<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128908</url>
  </required_header>
  <id_info>
    <org_study_id>05IAT0061</org_study_id>
    <secondary_id>2004040 - Dutch AIDS Fund</secondary_id>
    <nct_id>NCT00128908</nct_id>
  </id_info>
  <brief_title>Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients</brief_title>
  <official_title>Sequential HAART in Treatment Resistant HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch AIDS Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, crossover pilot study to explore the safety and efficacy of a rapid
      cycling regimen of antiretroviral combination therapy in HIV-1 infected patients with virus
      harboring genotypic resistance to at least three classes of antiretroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mathematical modeling has suggested that cyclic use of antiretroviral therapy can be an
      effective strategy in lowering viral load in HIV-1 infected patients when regular triple drug
      combinations have lost efficacy due to the emergence of HIV resistance mutations.

      This is an open label, crossover pilot study to explore the safety and efficacy of a rapid
      cycling regimen of antiretroviral combination therapy in HIV-1 infected patients with virus
      harboring genotypic resistance to at least three classes of antiretroviral therapy.

      The objectives are to study the feasibility, safety and efficacy of sequential combination
      therapy in HIV-1 infected patients with virus harboring genotypic resistance to at least
      three classes of antiretroviral agents and who currently have no adequate treatment options
      available.

      This is an open-label, crossover, pilot study. Patients that fail their current regimen, and
      who currently have no adequate treatment options left, will be randomized to start either an
      alternating triple combination, or to start a continuous quadruple regimen of drugs. After 6
      weeks, patients will crossover from either strategy to the other strategy for another 6
      weeks. Each period is preceded by an interruption of all antiretroviral therapy for 4 weeks.
      In the study period when regimens are alternated, two combinations of three drugs with the
      least possible cross-resistance will alternate every week.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Did not recruit
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma HIV-1 RNA load</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the genotype of the dominant quasispecies</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Replicative fitness of the dominant quasispecies</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ and CD8+ cell counts</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Continuous triple-class therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with a regimen containing antiretroviral agents from 3 different classes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alternating therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be assigned to weekly alternating dual-class regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Continuous Highly Active Antiretroviral Therapy (HAART)</intervention_name>
    <arm_group_label>Continuous triple-class therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapidly Cycled HAART</intervention_name>
    <arm_group_label>Alternating therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected patients

          -  At least 18 years of age

          -  Males or non-pregnant, non-lactating females

          -  Documented virological treatment failure on at least 3 classes of antiretroviral drugs

          -  No adequate antiretroviral therapy possible with currently available antiretroviral
             agents

          -  Virological treatment failure is defined as plasma HIV-1 RNA levels &gt; 5000 while
             taking at least three different antiretroviral drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joep MA Lange, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferdinand Wit, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV Outpatient Clinic, Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. J. Prins</name_title>
    <organization>Academic Medical Center, Amsterdam</organization>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HAART</keyword>
  <keyword>sequential HAART</keyword>
  <keyword>resistance</keyword>
  <keyword>salvage therapy</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

